Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지

Prevalence and Survival Patterns of Patients with Bone Metastasis from Common Cancers in Thailand

  • Phanphaisarn, Areerak (Department of Clinical Epidemiology, Faculty of Medicine, Thammasat University) ;
  • Patumanond, Jayantorn (Department of Clinical Epidemiology, Faculty of Medicine, Thammasat University) ;
  • Settakorn, Jongkolnee (Orthopedic Laboratory and Research Netting Center (OLARN Center), Department of Orthopedics, Faculty of Medicine, Chiang Mai University) ;
  • Chaiyawat, Parunya (Orthopedic Laboratory and Research Netting Center (OLARN Center), Department of Orthopedics, Faculty of Medicine, Chiang Mai University) ;
  • Klangjorhor, Jeerawan (Orthopedic Laboratory and Research Netting Center (OLARN Center), Department of Orthopedics, Faculty of Medicine, Chiang Mai University) ;
  • Pruksakorn, Dumnoensun (Orthopedic Laboratory and Research Netting Center (OLARN Center), Department of Orthopedics, Faculty of Medicine, Chiang Mai University)
  • Published : 2016.09.01
⟨ Previous Next ⟩

Abstract

Background: Bone metastasis is a single condition but presents with various patterns and severities. Skeletal-related events (SREs) deteriorate overall performance status and reduce quality of life. However, guidelines for early detection and management are limited. This study includes a survey of the prevalence of bone metastasis in cases with common cancers in Thailand as well as a focus on survival patterns and SREs. Materials and Methods: A retrospective cohort analysis was conducted using a database of the Chiang Mai Cancer Registry and the Musculoskeletal Tumor Registry of the OLARN Center, Chiang Mai University. The prevalence of bone metastasis from each type of primary cancer was noted and time-to-event analysis was performed to estimate cancer survival rates after bone metastasis. Results: There were 29,447 cases of the ten most common cancers in Thailand, accounting for 82.2% of the entire cancer registry entries during the study period. Among those cases, there were 2,263 with bone metastases, accounting for 7.68% of entries. Bone metastasis from lung, liver, breast, cervix and prostate are common in the Thai population, accounting for 83.4% of all positive cases. The median survival time of all was 6 months. Of the bone metastases, 48.9% required therapeutic intervention, including treatment of spinal cord and nerve root compression, pathological fractures, and bone pain. Conclusions: The frequency of the top five types of bone metastasis in Thailand were different from the frequencies in other countries, but corresponded to the relative prevalence of the cancers in Thailand and osteophilic properties of each cancer. The results of this study support the establishment of country specific guidelines for primary cancer identification with skeletal lesions of unknown origin. In addition, further clinical studies of the top five bone metastases should be performed to develop guidelines for optimal patient management during palliative care.

Keywords

Acknowledgement

Supported by : Chiang Mai University

References

  1. Abbas A, Medvedev S, Shores N, et al (2014). Epidemiology of metastatic hepatocellular carcinoma, a nationwide perspective. Dig Dis Sci, 59, 2813-20. https://doi.org/10.1007/s10620-014-3229-9
  2. Bae HM, Lee SH, Kim TM, et al (2012). Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis. Lung Cancer, 77, 572-7. https://doi.org/10.1016/j.lungcan.2012.05.094
  3. Coleman RE (2001). Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev, 27, 165-76. https://doi.org/10.1053/ctrv.2000.0210
  4. Coleman RE (2006). Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res, 12, 6243s-9s. https://doi.org/10.1158/1078-0432.CCR-06-0931
  5. D'Addario G, Fruh M, Reck M, et al (2010). Metastatic nonsmall-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21, 116-9. https://doi.org/10.1093/annonc/mdq189
  6. Goodwin CR, Abu-Bonsrah N, Boone C, et al (2016). Nonhepatocellular carcinoma spinal metastases. J Clin Neurosci, 27, 22-7. https://doi.org/10.1016/j.jocn.2015.11.003
  7. Habermehl D, Haase K, Rieken S, et al (2011). Defining the role of palliative radiotherapy in bone metastasis from primary liver cancer: an analysis of survival and treatment efficacy. Tumori, 97, 609-13. https://doi.org/10.1177/030089161109700512
  8. Ibrahim T, Mercatali L, Amadori D (2013). A new emergency in oncology: Bone metastases in breast cancer patients (Review). Oncol Lett, 6, 306-10. https://doi.org/10.3892/ol.2013.1372
  9. Katayose Y, Nakagawa K, Yamamoto K, et al (2012). Lymph nodes metastasis is a risk factor for bone metastasis from extrahepatic cholangiocarcinoma. Hepatogastroenterol, 59, 1758-60.
  10. Khuntikeo N, Chamadol N, Yongvanit P, et al (2015). Cohort profile: cholangiocarcinoma screening and care program (CASCAP). BMC Cancer, 15, 459. https://doi.org/10.1186/s12885-015-1475-7
  11. Kim SU, Kim DY, Park JY, et al (2008). Hepatocellular carcinoma presenting with bone metastasis: clinical characteristics and prognostic factors. J Cancer Res Clin Oncol, 134, 1377-84. https://doi.org/10.1007/s00432-008-0410-6
  12. Li S, Peng Y, Weinhandl ED, et al (2012). Estimated number of prevalent cases of metastatic bone disease in the US adult population. Clin Epidemiol, 4, 87-93.
  13. Liede A, Jerzak KJ, Hernandez RK, et al (2016). The incidence of bone metastasis after early-stage breast cancer in Canada. Breast Cancer Res Treat, 156, 587-95. https://doi.org/10.1007/s10549-016-3782-3
  14. Makino H, Nishio S, Tsubamoto H, et al (2016). Treatment and prognosis of bone metastasis from cervical cancer (KCOGG1202s). J Obstet Gynaecol Res.
  15. McDougall JA, Bansal A, Goulart BH, et al (2016). The clinical and economic impacts of skeletal-related events among medicare enrollees with prostate cancer metastatic to bone. Oncologist, 21, 320-6. https://doi.org/10.1634/theoncologist.2015-0327
  16. Nguyen DX, Bos PD, Massague J (2009). Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer, 9, 274-84. https://doi.org/10.1038/nrc2622
  17. Oster G, Lamerato L, Glass AG, et al (2013). Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer, 21, 3279-86. https://doi.org/10.1007/s00520-013-1887-3
  18. Paholpak P, Sirichativapee W, Wisanuyotin T, et al (2012). Prevalence of known and unknown primary tumor sites in spinal metastasis patients. Open Orthop J, 6, 440-4. https://doi.org/10.2174/1874325001206010440
  19. Qiu ZL, Song HJ, Xu YH, et al (2011). Efficacy and survival analysis of 131I therapy for bone metastases from differentiated thyroid cancer. J Clin Endocrinol Metab, 96, 3078-86. https://doi.org/10.1210/jc.2011-0093
  20. Singh VA, Haseeb A, Alkubaisi AA (2014). Incidence and outcome of bone metastatic disease at University Malaya Medical Centre. Singapore Med J, 55, 539-46. https://doi.org/10.11622/smedj.2014138
  21. Sugino K, Kameyama K, Nagahama M, et al (2014). Follicular thyroid carcinoma with distant metastasis: outcome and prognostic factor. Endocr J, 61, 273-9. https://doi.org/10.1507/endocrj.EJ13-0437
  22. Takagi T, Katagiri H, Kim Y, et al (2015). Skeletal Metastasis of Unknown Primary Origin at the Initial Visit: A Retrospective Analysis of 286 Cases. PLoS One, 10, 129428.
  23. Tanaka R, Yonemori K, Hirakawa A, et al (2016). Risk factors for developing skeletal-related events in breast cancer patients with bone metastases undergoing treatment with bone-modifying agents. Oncologist, 21, 508-13. https://doi.org/10.1634/theoncologist.2015-0377
  24. Tarnoki DL, Tarnoki AD, Ohlmann-Knafo S, et al (2016). Pattern of Tumour Spread of Common Primary Tumours as Seen on Magnetic Resonance Imaging. Pathol Oncol Res, 22, 79-85. https://doi.org/10.1007/s12253-015-9975-y
  25. Thanapprapasr D, Nartthanarung A, Likittanasombut P, et al (2010). Bone metastasis in cervical cancer patients over a 10-year period. Int J Gynecol Cancer, 20, 373-8. https://doi.org/10.1111/IGC.0b013e3181d4a0a1
  26. Thunyaharn N, Promthet S, Wiangnon S, et al (2013). Survival of cholangiocarcinoma patients in northeastern Thailand after supportive treatment. Asian Pac J Cancer Prev, 14, 7029-32. https://doi.org/10.7314/APJCP.2012.14.11.7029
  27. Tomita K, Kawahara N, Kobayashi T, et al (2001). Surgical strategy for spinal metastases. Spine, 26, 298-306. https://doi.org/10.1097/00007632-200102010-00016
  28. Tsuya A, Kurata T, Tamura K, et al (2007). Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer, 57, 229-32. https://doi.org/10.1016/j.lungcan.2007.03.013
  29. Uchino K, Tateishi R, Shiina S, et al (2011). Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer, 117, 4475-83. https://doi.org/10.1002/cncr.25960
  30. Zoccali C, Skoch J, Walter CM, et al (2016). The Tokuhashi score: effectiveness and pitfalls. Eur Spine J, 25, 673-8. https://doi.org/10.1007/s00586-015-4339-6